Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

145
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
145
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

181
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
181
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

355
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
355
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

129
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
129
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

7.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors-the PAC-WOMAN trial.

Frontiers in pain research (Lausanne, Switzerland)·2026
Same author

Publisher Correction: Reproducibility and robustness of economics and political science research.

Nature·2026
Same author

Healthcare professionals' beliefs on promoting physical activity in oncology: a COM-B framework analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Reproducibility and robustness of economics and political science research.

Nature·2026
Same author

Socioeconomic burden of multiple sclerosis: Insights from a cohort in Coimbra, Portugal.

Multiple sclerosis and related disorders·2026
Same author

[ACEIs versus ARBs, how to choose?]

Revue medicale suisse·2026

Related Experiment Video

Updated: Nov 15, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.2K

Phospholipase A2 and Ischemic Stroke Etiology.

Joana Ramos-Lopes1, Ricardo Varela1, Rui Pascoal1

  • 1Departments of Neurology.

The Neurologist
|March 1, 2021
PubMed
Summary

Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels vary among ischemic stroke subtypes, notably lower in embolic stroke of undetermined source (ESUS). This suggests distinct pathophysiological mechanisms in ESUS, requiring further multicenter trials for clarification.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

1.3K

Related Experiment Videos

Last Updated: Nov 15, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.2K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

1.3K

Area of Science:

  • Neuroscience
  • Cardiology
  • Biochemistry

Background:

  • Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory marker linked to atheromatous vascular events.
  • While its role in coronary disease is established, its impact on cerebrovascular etiology remains unclear.

Purpose of the Study:

  • To investigate the association between Lp-PLA2 levels and the etiologic subtypes of ischemic stroke.
  • To explore potential differences in Lp-PLA2 levels across various stroke classifications.

Main Methods:

  • A prospective cohort study of 96 acute ischemic stroke patients was conducted.
  • Lp-PLA2 levels were measured in peripheral blood between days 3-14 post-event.
  • Statistical analysis identified significant differences between etiologies (P<0.05).

Main Results:

  • Lp-PLA2 levels differed significantly across ischemic stroke etiologies (P=0.035).
  • Patients with embolic stroke of undetermined source (ESUS) exhibited lower Lp-PLA2 levels (143.3±42.8 ng/mL).
  • No significant associations were found with vascular risk factors or post-stroke functional outcomes (mRS).

Conclusions:

  • Lp-PLA2 levels are demonstrably different among ischemic stroke subtypes.
  • Lower Lp-PLA2 levels in ESUS patients suggest unique pathophysiological pathways.
  • Larger, multicenter trials are necessary to fully elucidate Lp-PLA2's role in stroke etiology.